Biopharmaceutical firm Clearside Biomedical Inc (NASDAQ:CLSD) has disclosed that results for the fourth quarter of 2017 as well as the full year will be released later this week. A conference call and a live webcast will be hosted once the results are released with a view to discussing the said financial report as well as to offer a general strategic and business review.
This comes in the wake of Clearside Biomedical disclosing that a treatment it had developed for improving vision in instances where there was a fluid buildup in the eyes of patients had turned out to be successful in a late-phase trial. According to Clearside Biomedical around 47% of the patients who received the treatment known as suprachoroidal CLS-TA were able to see a minimum of 15 letters. This contrasted with the 16% of trial participants who had undergone a placebo procedure.
The biopharmaceutical firm now intends to have a marketing application filed with the U.S. Food and Drug Administration in Q4.
“We currently expect to submit a new drug application for suprachoroidal CLS-TA in patients with macular edema associated with uveitis to the FDA in the fourth quarter of 2018… [as well as to] additional territories outside of the United States,” the president and chief executive officer of Clearside Medical, Daniel White, said.
Clearside’s treatment was tested on patients suffering from macular edema whereby symptoms include inflammation in the uveitis. In the trial 160 patients were enrolled where 64 of them received a placebo and 96 got the treatment. Evaluation of the patients was conducted once every two fortnights for 24 weeks. Approximately 97% of the patients or 155 in absolute terms were able to complete the trial.
Late last month the biopharmaceutical firm conducted organizational changes and this include the appointment of a new board chairman as well as some senior executive appointments. This saw William Humphries become Clearside Medical’s new board chairman following the stepping down of Christy Shaffer.
Prior to rising to the position of chairman Humphries had been a director of the biopharmaceutical firm for six years now. Humphries has also been in the pharmaceutical sector for close to three decades.